NCT00659529已完成1 期
The Role of Phosphodiesterase Inhibitors in CF Lung Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Sputum Elastase
研究概览
简要总结
The purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.
详细描述
This study is an open-label study that examines the use of sildenafil (Revatio) in clinically stable patients with mild to moderate CF lung disease. The length of participation for each subject will be approximately 10 weeks, and will consist of a screening visit, a study visit for initiation of study drug if subject qualifies, interim visits to escalate drug dose, obtain drug levels, review concomitant medications and assess side effects, a visit at the end of the therapy period (to reassess inflammatory markers, laboratory studies and side effects,) and a follow-up assessment 2 weeks after subject completion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of CF based on the following criteria:
- •Positive sweat chloride ≥60mEq/liter (by pilocarpine iontophoresis) and/or
- •Genotype with two identifiable mutations consistent with CF, and accompanied by one or more clinical features consistent with the CF phenotype
- •Male or female patients ≥ 12 years of age
- •FEV1 ≥ 50% predicted (Knudson) 31
- •Clinically stable without evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation within the 14 days prior to the screening visit
- •Ability to reproducibly perform spirometry (according to ATS criteria)
- •Ability to produce at least 1mL of sputum spontaneously, or be willing to undergo sputum induction
- •Ability to understand and sign a written informed consent or assent and comply with the requirements of the study
- •Chronic bacterial colonization (3 documented positive cultures in the prior 2 years of which at least one was obtained in the 3 months prior to randomization)
排除标准
- •History of hypersensitivity to sildenafil
- •Use of an investigational agent within the 4-week period prior to Visit 1 (Day 0)
- •Breastfeeding, pregnant, or verbal expression of unwillingness to practice an acceptable birth control method (abstinence, hormonal or barrier methods, partner sterilization or intrauterine device) during participation in the study
- •Daily use of systemic corticosteroids and/or NSAIDs within 4 weeks of the study or as needed use within 72 hours prior to the screening visit
- •History of significant hepatic (SGOT or SGPT > 3 times the upper limit of normal at screening, documented biliary cirrhosis, or portal hypertension), cardiovascular (history of aortic stenosis, coronary artery disease, pulmonary hypertension with right ventricular systolic pressure >55 mmHg or life-threatening arrhythmia), neurological (history of stroke), hematologic (history of bleeding diathesis), ophthalmologic (history of retinal impairment or non-arteritic ischemic optic neuritis) or renal impairment (creatinine >1.8 mg/dL.)
- •Inability to swallow pills
- •Previous lung transplantation
- •Use of concomitant nitrates, α-blocker, or Ca channel blocker
- •Use of concomitant medications known to be potent inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin, rifampin)
- •Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the subject or the quality of the data
- •Weight less than 40 kg
- •History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years of screening
- •Resting room air oxygen saturation <93%
- •History of migraines
结局指标
主要结局
Sputum Elastase
时间窗: Pre/post therapy
次要结局
- Exhaled Breath Condensate pH(Pre/post therapy)
- Serum Sildenafil Levels(Pre/during therapy)
- CFQ-R(Pre/post therapy)
研究者
Jennifer Taylor-Cousar
Principal Investigator
National Jewish Health
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary HypertensionCOPDPulmonary HypertensionNCT01055405Hospital Clinic of Barcelona65
已完成
不适用
Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary HypertensionGroup 2 Pulmonary HypertensionCpcPHNCT06350773Beni-Suef University66
已完成
3 期
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PHHeart Failure, DiastolicPulmonary HypertensionNCT01726049University Medical Center Groningen52
已完成
1 期
The Role of Phosphodiesterase Inhibitors in Incretin SecretionHealthy VolunteersNCT02363335National Institute on Aging (NIA)29
已完成
3 期
Evaluating the effect of sildenafil on the treatment of severe asthmaAsthma.AsthmaIRCT20140518017738N2Ahvaz University of Medical Sciences20